LncRNA LINC01857 reduces metastasis and angiogenesis in breast cancer cells via regulating miR-2052/CENPQ axis.

IF 1.6

Open medicine (Warsaw, Poland) Pub Date : 2022-08-10 eCollection Date: 2022-01-01 DOI:10.1515/med-2022-0525

Weiwei Qian, Linlin Yang, Yi Ni, Fei Yin, Lili Qin, Yang Yang

{"title":"LncRNA LINC01857 reduces metastasis and angiogenesis in breast cancer cells via regulating miR-2052/CENPQ axis.","authors":"Weiwei Qian, Linlin Yang, Yi Ni, Fei Yin, Lili Qin, Yang Yang","doi":"10.1515/med-2022-0525","DOIUrl":null,"url":null,"abstract":"Long non-coding RNAs have been confirmed closely related to the metastasis and angiogenesis of breast cancer (BC). LINC01857 can promote the growth and metastasis of BC cells. The present work focused on exploring the role of LINC01857 in BC metastasis and angiogenesis and investigating the possible mechanisms. The results showed that LINC01857 and CENPQ were highly expressed in BC tissues and cells, while miR-2052 was contrarily expressed. In vitro study showed that low expression of linc01857 could inhibit the migration ability and vascularization of BC cells, and mir-2052 inhibitor partially restored the effect of si-LINC01857 on the migration ability and vascularization of BC cells. Likewise, inhibition of CENPQ can partially rescue the effects of miR-2052 inhibitor on the migration ability and vascularization of BC cells. In vivo studies showed that down-regulation of LINC01857 notably suppressed tumor growth and angiogenesis in nude mice. The miR-2052 inhibitor partially restored the effects of si-LINC01857. CENPQ suppression partially rescued the effects of the miR-2052 inhibitor. To conclude, LINC01857/miR-2052/CENPQ is the potential novel target for BC treatment.","PeriodicalId":520729,"journal":{"name":"Open medicine (Warsaw, Poland)","volume":" ","pages":"1357-1367"},"PeriodicalIF":1.6000,"publicationDate":"2022-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372711/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open medicine (Warsaw, Poland)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2022-0525","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Long non-coding RNAs have been confirmed closely related to the metastasis and angiogenesis of breast cancer (BC). LINC01857 can promote the growth and metastasis of BC cells. The present work focused on exploring the role of LINC01857 in BC metastasis and angiogenesis and investigating the possible mechanisms. The results showed that LINC01857 and CENPQ were highly expressed in BC tissues and cells, while miR-2052 was contrarily expressed. In vitro study showed that low expression of linc01857 could inhibit the migration ability and vascularization of BC cells, and mir-2052 inhibitor partially restored the effect of si-LINC01857 on the migration ability and vascularization of BC cells. Likewise, inhibition of CENPQ can partially rescue the effects of miR-2052 inhibitor on the migration ability and vascularization of BC cells. In vivo studies showed that down-regulation of LINC01857 notably suppressed tumor growth and angiogenesis in nude mice. The miR-2052 inhibitor partially restored the effects of si-LINC01857. CENPQ suppression partially rescued the effects of the miR-2052 inhibitor. To conclude, LINC01857/miR-2052/CENPQ is the potential novel target for BC treatment.

Abstract Image

查看原文本刊更多论文

LncRNA LINC01857通过调节miR-2052/CENPQ轴减少乳腺癌细胞的转移和血管生成。

长链非编码rna已被证实与乳腺癌的转移和血管生成密切相关。LINC01857能促进BC细胞的生长和转移。本文主要探讨LINC01857在BC转移和血管生成中的作用，并探讨其可能的机制。结果显示，LINC01857和CENPQ在BC组织和细胞中高表达，而miR-2052表达相反。体外研究表明，低表达linc01857可抑制BC细胞的迁移能力和血管形成，mir-2052抑制剂可部分恢复si-LINC01857对BC细胞迁移能力和血管形成的影响。同样，抑制CENPQ可以部分恢复miR-2052抑制剂对BC细胞迁移能力和血管化的影响。体内研究表明，下调LINC01857显著抑制裸鼠肿瘤生长和血管生成。miR-2052抑制剂部分恢复了si-LINC01857的作用。抑制CENPQ部分地挽救了miR-2052抑制剂的作用。总之，LINC01857/miR-2052/CENPQ是BC治疗的潜在新靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open medicine (Warsaw, Poland)

自引率

0.00%

发文量